Work

Supplementary Table S1 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

Year: 2023

Type: supplementary-materials

Abstract: Clinical characteristics of the cohorts included in study. Of note, the Seiler cohort pathological tumor stage is after neoadjuvant chemotherapy (i.e. ypT). ** age > 90 censored to protect patient privacy

DOI: 10.1158/1078-0432.22481565

Authors: Carissa E. Chu, Martin Sjöström, Emily A. Egusa, Ewan A. Gibb, Michelle L. Badura, Jun Zhu, Vadim S. Koshkin, Bradley A. Stohr, Maxwell V. Meng, Raj S. Pruthi, Terence W. Friedlander, Yair Lotan, Peter C. Black, Sima P. Porten, Felix Y. Feng, Jonathan Chou

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361890120

Cites:

Cited by:

Related to: 10